Market Trends of Global Polycystic Ovarian Syndrome Treatment Industry
This section covers the major market trends shaping the Polycystic Ovarian Syndrome Treatment Market according to our research experts:
Laparoscopic Ovarian Drilling is Expected to Hold Major Share Under Surgeries Over the Forecast Period
Laparoscopic ovarian drilling (LOD) is one of the most common surgeries doctors perform in critical conditions. Since women's fertility problems are quite predominant because of PCOS, and response to medications weakens over time, the surgery performed via a thin microscope through the abdomen is majorly preferred across the geography. As per the study titled "Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome," published in the Cochrane Library in July 2020, According to evidence, if the chance of a live birth following medical ovulation induction alone is 42%, the chance of a live birth following LOD is between 28% and 40%. The study suggested a high success rate in laparoscopic drilling in women, which is why it is most preferred. In addition, the cost-effective procedures drive patients toward this surgical procedure for easy treatment of the disease. Thus, it is estimated to have a significant share over the forecast period.
However, the COVID-19 pandemic has had ramifications for ways of working of various surgical procedures, including laparoscopic ovarian drilling. In May 2020, University of Birmingham Experts at the University of Birmingham-led NIHR Global Research Health Unit on Global Surgery published their findings that the patients undergoing surgery after contracting coronavirus are at increased risk of postoperative death and are recommended to avoid all non-emergent surgeries. But, later, the regulatory bodies, to keep the normal surgical procedures going on, imposed a few guidelines specific to each specialty that must be implemented and followed for the surgeons to continue to provide safe and effective care to their patients during the COVID-19 pandemic. These issued guidelines have allowed healthcare providers to resume their surgery practices. Thus, it is expected that laparoscopic ovarian drilling procedures will also regain their normal growth in the future.
North America is Estimated to Have Largest Share in the Global Market
The rising prevalence of obesity and overweight people is leading to an increase in the number of people with PCOS, which is one of North America's major drivers of market growth. Furthermore, as people become more aware of the benefits of regular checkups, the number of new cases diagnosed yearly in this region is rising. Obesity, considered a major risk factor for PCOS, has seen an upsurge during the pandemic. In September 2020, the Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, lesser physical activities, and financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 %, including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia. The data by CDC revealed that there is a high prevalence of obesity in North American countries, which is going to increase the risk of PCOS and is anticipated to offer positive growth to the market.
The United States and Canada are highly advanced in procuring new technology and early release of drugs in the market. This region has a major player base and a strong product pipeline to propel market growth. For instance, in Jan 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome, which is expected to drive the market during the forecast period.
Additionally, in January 2020, Abbvie had an active clinical trial with the molecule Elagolix in the pipeline, which is being evaluated for its safety and efficacy in women with polycystic ovary syndrome. Currently, the company has a Phase 2, multicenter, double-blind, randomized, placebo-controlled study going on to assess the safety and efficacy of Elagolix in women with polycystic ovary syndrome (PCOS).
The need to ease the treatment and procedures has evolved significantly in the past decade, pushing several R&D investments and venture partners funding for pharmaceutical companies in this region, thus driving the market growth.
